The appearance of troglitazone, a potent insulin-sensitizing agent, marked a important chapter in the control of type 2 diabetes. However, its discontinuation from the market due to substantial hepatotoxicity spurred considerable investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering analogous m